Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 8:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 2,226 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: ADD Clear all
Completed No phase listed Observational

Modulation of Behavioral Inhibition in Attention Deficit Hyperactivity Disorder

NCT02290899
View directory record Official record
Conditions
ADHD
Interventions
Not listed
Lead sponsor
Rhode Island Hospital
Other
Eligibility
10 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
East Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 10, 2017 · Synced Oct 29, 2026, 8:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

dHealth Solution for Improving Parent Adherence to Behavioral Treatment for ADHD

NCT04025814
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
CaregiverAssist, Behavioral Parent Training (CLS Parent Group)
Device · Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
6 Years to 85 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Oct 29, 2026, 8:41 PM EDT
Active, not recruiting Phase 3 Interventional

Treating Schizophrenia by Correcting Abnormal Brain Development

NCT00179465
View directory record Official record
Conditions
Schizophrenia
Interventions
Tiagabine, Placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 25 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 27, 2025 · Synced Oct 29, 2026, 8:41 PM EDT
Completed Phase 4 Interventional Results available

XeNA Study - A Study of Xeloda (Capecitabine) in Patients With Invasive Breast Cancer

NCT00127933
View directory record Official record
Conditions
Breast Cancer
Interventions
capecitabine [Xeloda], Taxotere, Herceptin (HER2-neu positive patients only)
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older · Female only
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
38
States / cities
Los Angeles, California • Montebello, California • Palm Springs, California + 30 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2011 · Synced Oct 29, 2026, 8:41 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Brain Activity Flow Patterns Analysis Using Evoked Response Potentials in Youth With ADHD, Bipolar Disorder, or Autism Spectrum Disorders: A Preliminary Study

NCT01506232
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, Autism Spectrum Disorder, Bipolar Disorder
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Years to 17 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 28, 2024 · Synced Oct 29, 2026, 8:41 PM EDT
Completed Phase 2 Interventional Results available

Open-label, Single-dose Trial to Assess the Pharmacokinetics of Centanafadine Extended-release Capsules in Pediatric Participants With Attention-deficit Hyperactivity Disorder (ADHD)

NCT04081363
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Centanafadine
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
9 Years to 12 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 13, 2023 · Synced Oct 29, 2026, 8:41 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Improving Social, Emotional, Behavioral, and Academic Functioning

NCT05425381
View directory record Official record
Conditions
Depression, Anxiety, Disruptive Behavior Disorder, Trauma, Psychological
Interventions
Enhanced version of Interconnected Systems Framework, Positive Behavioral Interventions and Supports with Co-located School Mental Health
Behavioral
Lead sponsor
East Carolina University
Other
Eligibility
Not listed
Enrollment
1,208 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
2
States / cities
Greenville, North Carolina • Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 21, 2022 · Synced Oct 29, 2026, 8:41 PM EDT
Terminated Phase 2 Interventional Results available

Low Dose Aprepitant for Patients Receiving Carboplatin

NCT03237611
View directory record Official record
Conditions
Chemotherapy-induced Nausea and Vomiting
Interventions
Aprepitant 125 mg, Fosaprepitant 115 MG, Dexamethasone, Ondansetron 16 MG
Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Oct 29, 2026, 8:41 PM EDT
Completed Not applicable Interventional

Subacute Effects of Spinal Mobilization to Treat Subacromial Impingement

NCT01753271
View directory record Official record
Conditions
Subacromial Impingement Syndrome
Interventions
thoracic mobilization & shoulder mobilization & exercise, shoulder mobilization & exercise
Other
Lead sponsor
High Point University
Other
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
3
States / cities
Chicago, Illinois • Elizabethton, Tennessee • Johnson City, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 20, 2015 · Synced Oct 29, 2026, 8:41 PM EDT
Completed Phase 3 Interventional

A Clinical Study to Compare an Aliskiren Based Hypertensive Regimen With a Ramipril Based One Followed by a Randomized Withdrawal.

NCT00219063
View directory record Official record
Conditions
Hypertension
Interventions
aliskiren
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
844 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated May 17, 2017 · Synced Oct 29, 2026, 8:41 PM EDT
Completed Phase 1 Interventional Results available

Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL

NCT04134936
View directory record Official record
Conditions
Diffuse Large B-cell Lymphoma
Interventions
Tafasitamab, Tafasitamab plus lenalidomide
Drug
Lead sponsor
MorphoSys AG
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
23
States / cities
Tucson, Arizona • Anaheim, California • Duarte, California + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2024 · Synced Oct 29, 2026, 8:41 PM EDT
Not listed Phase 4 Interventional

Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk

NCT03781765
View directory record Official record
Conditions
ADHD, Attention Deficit Hyperactivity Disorder
Interventions
Methylphenidate, Atomoxetine
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
7 Years to 12 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 9, 2024 · Synced Oct 29, 2026, 8:41 PM EDT
Not listed Not applicable Interventional

Investigating the Effects of Parent Component to Cognitive Behavior Therapy (CBT) for Youth With Anxiety Disorders

NCT02160444
View directory record Official record
Conditions
Anxiety Disorders
Interventions
CBT plus Parent as CBT Coach Training
Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
7 Years to 17 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 12, 2016 · Synced Oct 29, 2026, 8:41 PM EDT
Completed Not applicable Interventional Results available

Research Study to Test Safety and Effectiveness of Investigational Drug in Patients With Trigeminal Neuralgia

NCT00203229
View directory record Official record
Conditions
Trigeminal Neuralgia
Interventions
lamotrigine, Placebo
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
15 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 3, 2014 · Synced Oct 29, 2026, 8:41 PM EDT
Terminated Phase 2 Interventional Results available

High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma

NCT01434472
View directory record Official record
Conditions
Post-Transplant Lymphoproliferative Disorder, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Burkitt Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Burkitt Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Cyclosporine, Fludarabine Phosphate, Indium In-111 Ibritumomab Tiuxetan, Mycophenolate Mofetil, Pharmacological Study, Rituximab, Total-Body Irradiation, Yttrium Y-90 Ibritumomab Tiuxetan, Fludarabine
Procedure · Drug · Radiation + 2 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 20, 2021 · Synced Oct 29, 2026, 8:41 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Risk of Attention Deficit Hyperactivity Disorder (ADHD) in the Children of Adults With ADHD Not Otherwise Specified (NOS)

NCT00181857
View directory record Official record
Conditions
ADHD
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 31, 2013 · Synced Oct 29, 2026, 8:41 PM EDT
Completed Phase 4 Interventional Results available

Efficacy of Omalizumab in Adults (18-60 Years of Age) With Moderate-Severe, Persistent Allergic Asthma, Despite Receiving Inhaled Corticosteroids and Long Acting Beta-agonists

NCT00670930
View directory record Official record
Conditions
Allergic Asthma
Interventions
omalizumab at a dose of 0.016mg/kg/IU/mL, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
6
States / cities
Denver, Colorado • St Louis, Missouri • Durham, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2013 · Synced Oct 29, 2026, 8:41 PM EDT
Recruiting Phase 4 Interventional

AWARE: Management of ADHD in Autism Spectrum Disorder

NCT05916339
View directory record Official record
Conditions
ADHD, Autism Spectrum Disorder
Interventions
Randomization to either Amphetamine (AMP) class of stimulant medication or Methylphenidate (MPH) class of stimulant medication, Randomization to either Alpha 2 agonist class of medication or alternate class of stimulant.
Drug
Lead sponsor
Daniel Coury
Other
Eligibility
4 Years to 17 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
11
States / cities
Irvine, California • Los Angeles, California • Portland, Maine + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 29, 2026, 8:41 PM EDT
Not listed Phase 1Phase 2 Interventional

Addition of Paclitaxel to High-Dose Combination Chemotherapy in Treating Women With Metastatic Breast Cancer

NCT00002628
View directory record Official record
Conditions
Breast Cancer
Interventions
filgrastim, carboplatin, cyclophosphamide, mesna, paclitaxel, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
St. Louis University
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1994
U.S. locations
3
States / cities
Indianapolis, Indiana • St Louis, Missouri • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 10, 2014 · Synced Oct 29, 2026, 8:41 PM EDT
Completed Phase 4 Interventional Results available

Study of Medication Patch to Treat Children Ages 6-12 With ADHD

NCT00586157
View directory record Official record
Conditions
ADHD, Attention Deficit Hyperactivity Disorder
Interventions
Methylphenidate Transdermal System, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Years to 12 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 16, 2012 · Synced Oct 29, 2026, 8:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Neuromodulation of Executive Function in the ADHD Brain

NCT04175028
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Transcranial Direct Current Stimulation
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 66 Years
Enrollment
83 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 12, 2025 · Synced Oct 29, 2026, 8:41 PM EDT
Completed Phase 2 Interventional

Rademikibart Add-on Treatment of an Acute COPD Exacerbation (Seabreeze STAT COPD)

NCT06940154
View directory record Official record
Conditions
COPD Acute Exacerbation
Interventions
Rademikibart in prefilled syringe, Matching placebo in prefilled syringe
Combination Product · Drug
Lead sponsor
Connect Biopharm LLC
Industry
Eligibility
40 Years to 80 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
21
States / cities
Birmingham, Alabama • Palo Alto, California • Valencia, California + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 29, 2026, 8:41 PM EDT
Completed Phase 3 Interventional Results available

A Randomized Study in Children Ages Birth Through Three Years Undergoing Unilateral Cataract Extraction With or Without Lens Replacement

NCT02132312
View directory record Official record
Conditions
Unilateral Cataract Extraction, Congenital Cataract
Interventions
OMS302, Phenylephrine HCl
Drug
Lead sponsor
Omeros Corporation
Industry
Eligibility
1 Day to 47 Months
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
11
States / cities
Los Angeles, California • Atlanta, Georgia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2021 · Synced Oct 29, 2026, 8:41 PM EDT
Completed Phase 2 Interventional Results available

A Study Comparing the Combination of the Best Supportive Care Plus E7080 Versus Best Supportive Care Alone, in Patients With Advanced Lung Cancer or Lung Cancer That Has Spread, Who Have Been Previously Treated, Unsuccessfully, With at Least 2 Different Treatments

NCT01529112
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Lenvatinib, Lenvatinib matched placebo, BSC
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
11
States / cities
Casa Grande, Arizona • Tucson, Arizona • Gilroy, California + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2017 · Synced Oct 29, 2026, 8:41 PM EDT